Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine

Transplantation

Volumn 62, Issue 11, 1996, Pages 1559-1564

  Goldberg, Ronald ^a   Roth, David ^b  

^a DIABETES RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SINGLE BLIND PROCEDURE;

ADULT; ANTICHOLESTEREMIC AGENTS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLACEBOS;

EID: 0030463459     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612150-00005     Document Type: Article

References (29)

1. United States Renal Data System. Excerpts from USRDS annual data report 1990. VI. Survival and mortality. Am J Kidney Dis 1990; 16 (suppl): 44.
2. Pirsch JD, D'Alessandro AM, Sollinger HW, et al. Hyperlipidemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol 1992; 2 (suppl 3): S238.
3. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987; 2: 10.
4. Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders. N Engl J Med 1985; 312: 1300.
5. Ferenchick G, Rovner D. Case report: hepatitis and hematemesis complicating nicotinic acid use. Am J Med Sci 1989; 298: 191.
6. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad ES, Grossman W. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 1989; 64: 725.
7. Tobert JA. Efficacy and long-term adverse effects pattern of lovastatin. Am J Cardiol 1988; 62: 28J.
8. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother 1992; 26: 190.
9. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47.
10. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. JAMA 1988; 260: 239.
11. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin [Letter]. N Engl J Med 1988; 318: 46.
12. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82 (suppl IV): IV-281.
13. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732.
14. Arnadottir M, Eriksson L-O, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410.
15. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 1225.
16. Chucrallah A, De Girolami U, Freeman R, Federman M. Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study. Eur Neurol 1992; 32: 293.
17. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73: 3D.
18. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med 1991; 151: 43.
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383.
20. Jukema JW, Bruschke AVG, van Boven AJ, et al on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528.
21. Holdaas H, Hartmann A, Stenstrøm J, Dahl K, Borge M, Pfister P. Fluvastatin lowers atherogenic lipids safely in renal-transplant patients taking cyclosporine. Paper presented at the 10th International Symposium on Atherosclerosis, Montreal, October 9-14, 1994.
22. Li PKT, Mak TWL, Wang AYM, et al. Interaction of fluvastatin and cyclosporine in renal-transplant patients with dyslipoproteinemia. Paper presented at the 10th International Symposium on Atherosclerosis, Montreal, October 9-14, 1994.
23. Kalafsky G, Smith HT, Choc MG. High-performance liquid chromatographic method for the determination of fluvastatin in human plasma. J Chromatogr B Biomed Appl 1993; 614: 307.
24. Dujovne CA, Davidson MH. Fluvastatin administration at bed-time versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy. Am J Med 1994; 96 (suppl 6A): 37S.
25. Data on File, Sandoz Pharmaceuticals Corp.
26. Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994; 120: 537.
27. Davidson MH. Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety. Am J Med 1994; 96 (suppl 6A): 41S.
28. Knopp RH, Frohlich J, Jokubaitis LA, Dawson K, Broyles FE, Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994; 96 (suppl 6A): 69S.
29. Berens KL, Vadiei K, Brunner LJ, Wasan KM, Luke DR. Influence of lovastatin on the pharmacokinetics, toxicity and immunologic response of cyclosporine in the obese Zucker rat. Biopharm Drug Dispos 1990; 11: 197.